Seeking Alpha

More on Amgen (AMGN): Q4 misses slightly on a per share basis due to higher sales costs, but...

More on Amgen (AMGN): Q4 misses slightly on a per share basis due to higher sales costs, but beats on revenue. Overall sales growth was positive, with strong performance coming from its two heavyweight drugs, Xgeva and Prolia, plus decent showings as well from Neupogen and Neulasta. The Company expects FY12 revenue in the range of $16.1B - $16.5B. Shares +0.8% AH.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector